Cancer Council Tasmania/UTAS Health Postdoctoral Research Fellow
27 Jan 2026 - 27 Jan 2028
People funded by this grant:
Wilkinson E
Project Total: $200,000; This project aims to explore a novel therapeutic option for glioblastoma (GBM), one of the most prevalent and aggressive types of brain cancer. GBM is characterised by rapid growth and invasiveness and is notoriously treatment resistant, leading to a poor prognosis. Current chemotherapeutic agents such as temozolomide (TMZ) are effective but insufficient to overcome the aggressive nature of GBM. Therefore, new approaches that can sensitise tumour cells to existing therapeutic agents like TMZ are an attractive approach to improving treatment options for GBM.
In this project, I will investigate the ability of antisense oligonucleotides (ASO) to sensitise cell line models of GBM to existing chemotherapeutic treatments. Initially this project will focus on determining the duration of ASO efficacy. Subsequently I will investigate the impact this has on cell viability, proliferation, and sensitivity to current chemotherapeutic agents following exposure to the ASOs. Funded by: Cancer Council of Tasmania - Donation ($300,000); University of Tasmania ($135,000).